The estimated Net Worth of Richard S Lindahl is at least $2.18 Million dollars as of 15 November 2021. Mr. Lindahl owns over 3,000 units of Emergent Biosolutions Inc stock worth over $302,187 and over the last 19 years he sold EBS stock worth over $0. In addition, he makes $1,877,500 as Chief Financial Officer, Executive Vice President und Treasurer at Emergent Biosolutions Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Lindahl EBS stock SEC Form 4 insiders trading
Richard has made over 2 trades of the Emergent Biosolutions Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of EBS stock worth $112,380 on 15 November 2021.
The largest trade he's ever made was exercising 49,374 units of Emergent Biosolutions Inc stock on 19 August 2005 worth over $420,666. On average, Richard trades about 1,746 units every 198 days since 2005. As of 15 November 2021 he still owns at least 39,919 units of Emergent Biosolutions Inc stock.
You can see the complete history of Mr. Lindahl stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Lindahl biography
Richard S. Lindahl is Chief Financial Officer, Executive Vice President, Treasurer of the Company since March 2018. Mr. Lindahl has more than two decades of financial leadership experience. Prior to joining us, Mr. Lindahl served as chief financial officer of CEB Inc., a best practice insight and technology company, from May 2009 until April 2017 and as its principal accounting officer until July 2015. At CEB, Mr. Lindahl was responsible for managing finance strategy and operations, tax and investor relations initiatives, overseeing the corporate real estate, facilities and procurement functions and serving as chair of its investments and acquisitions committee. From 2006 until 2008, Mr. Lindahl served as senior vice president and treasurer of Sprint Nextel Corporation and from 2005 to 2006, he served as vice president and treasurer of Sprint Nextel. From 1997 until 2005, Mr. Lindahl served in various positions at Nextel Communications, Inc., including as treasurer and in financial planning and analysis roles. Prior to joining Nextel, from 1995 until 1997, Mr. Lindahl held the position of vice president, finance at Pocket Communications, Inc. Before 1995, Mr. Lindahl held various positions at MCI Communications Corp., Deloitte & Touche LLP, and Casher Associates, Inc. Mr. Lindahl earned an M.B.A. from the Darden School at the University of Virginia and a B.A. in computer science from Dartmouth College.
What is the salary of Richard Lindahl?
As the Chief Financial Officer, Executive Vice President und Treasurer of Emergent Biosolutions Inc, the total compensation of Richard Lindahl at Emergent Biosolutions Inc is $1,877,500. There are 3 executives at Emergent Biosolutions Inc getting paid more, with Robert Kramer having the highest compensation of $3,693,820.
How old is Richard Lindahl?
Richard Lindahl is 56, he's been the Chief Financial Officer, Executive Vice President und Treasurer of Emergent Biosolutions Inc since 2018. There are 15 older and 6 younger executives at Emergent Biosolutions Inc. The oldest executive at Emergent Biosolutions Inc is Louis Sullivan, 86, who is the Independent Director.
What's Richard Lindahl's mailing address?
Richard's mailing address filed with the SEC is 300 PROFESSIONAL DRIVE, , GAITHERSBURG, MD, 20879.
Insiders trading at Emergent Biosolutions Inc
Over the last 18 years, insiders at Emergent Biosolutions Inc have traded over $131,382,266 worth of Emergent Biosolutions Inc stock and bought 4,647 units worth $138,981 . The most active insiders traders include Seamus Mulligan, Fuad El Hibri und Shahzad Malik. On average, Emergent Biosolutions Inc executives and independent directors trade stock every 21 days with the average trade being worth of $147,206. The most recent stock trade was executed by Kathryn C Zoon on 4 June 2024, trading 10,000 units of EBS stock currently worth $61,100.
What does Emergent Biosolutions Inc do?
emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent
What does Emergent Biosolutions Inc's logo look like?
Complete history of Mr. Lindahl stock trades at Emergent Biosolutions Inc
Emergent Biosolutions Inc executives and stock owners
Emergent Biosolutions Inc executives and other stock owners filed with the SEC include:
-
Robert Kramer,
President, Chief Executive Officer, Director -
Fuad El-Hibri,
Executive Chairman of the Board -
Robert G. Kramer,
CEO, Pres & Exec. Director -
Richard Lindahl,
Chief Financial Officer, Executive Vice President, Treasurer -
Atul Saran,
Executive Vice President, Corporate Development, General Counsel and Corporate Secretary -
Adam Havey,
Executive Vice President - Business Operations -
Fuad El-Hibri,
Founder & Exec. Chairman -
Richard S. Lindahl,
Exec. VP, CFO & Treasurer -
Adam R. Havey,
Exec. VP & COO -
Atul Saran,
Exec. VP of Corp. Devel. & Ext. Affairs and Gen. Counsel -
Seamus Mulligan,
Director -
Ronald Richard,
Lead Independent Director -
Zsolt Harsanyi,
Independent Director -
Louis Sullivan,
Independent Director -
Jerome Hauer,
Independent Director -
George Joulwan,
Independent Director -
Kathryn Zoon,
Independent Director -
Sue Bailey,
Independent Director -
Marvin White,
Director -
Robert Burrows,
Vice President, Investor Relations -
Sean Kirk,
Executive Vice President, Manufacturing and Technical Operations -
Katherine Strei,
Executive Vice President, Human Resources and Communications, Chief Human Resources Officer -
Katherine Strei,
Exec. VP of HR & Chief HR Officer -
Nina DeLorenzo,
Sr. VP of Global Communications & Public Affairs -
Lynn Kieffer,
VP of Corp. Communications -
Howard Anderson,
Sr. VP & Chief Information Officer -
Karen L. Smith,
EVP, Chief Medical Officer -
John Niederhuber,
Director -
Daniel Abdun Nabi,
SVP Corp Aff, GC & Secretary -
L.L.C. Bio Pharm,,
10% owner -
Stephen Lockhart,
SVP Product Development -
L.L.C. Intervac,,
10% owner -
Steven Chatfield,
President, EPD UK & CSO -
R Don Elsey,
VP Finance, CFO & Treasurer -
Barry Labinger,
EVP, Biosciences Div. -
Denise Esposito,
SVP Legal Affairs & GC -
L.L.C. Biologika,,
-
Biologic Products, Inc. Mic...,
-
Kyle Keese,
SVP Mktg & Comm. -
Joe M Allbaugh,
Director -
Mauro Gibellini,
SVP Corporate Dev. -
Investments Ltd Microscience,
10% owner -
Shahzad Malik,
Director -
Edward Arcuri,
EVP & COO -
Thomas Zink,
SVP & CMO -
Robert Calvin Myers,
-
Joseph C Papa,
President and CEO -
Jennifer Lynne Fox,
EVP, Ext Aff, GC, Corp Sec -
Keith Katkin,
Director -
Coleen Glessner,
EVP, Quality & Ethics, and CPL -
Sujata Tyagi Dayal,
Director -
Paul Anthony Williams,
SVP, Products Business -
William Hartzel,
SVP, Bioservices -
Neal Franklin Fowler,
Director -
Donald W De Golyer,
Director